Windtree Q3 net loss $4.4M ($0.86/share); cash $7.4M, runway to Q1 2024

WINDTREE THERAPEUTICS INC /DE/

Net loss of $4.4M ($0.86 per share) on 5.1M weighted-average shares; operating loss $4.7M.
Cash and equivalents $7.4M as of Sep 30, expected to fund operations through Q1 2024.
R&D expenses increased to $2.1M due to SEISMiC Extension study initiation; G&A stable at $2.6M.
Entered new ATM agreement with Ladenburg for up to $2.05M stock sales; prior ATM terminated.
Istaroxime program: SEISMiC Extension study underway; SCAI Stage C study expected to start Q4.

item 1.01 item 1.02 item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

WINDTREE THERAPEUTICS INC /DE/ reported third quarter ended September 30, 2023 results: net income net loss of $4.4 million, EPS $0.86 per basic share.

Period: third quarter ended September 30, 2023
Net income: net loss of $4.4 million
EPS: $0.86 per basic share
Result: reported results

Exact text from the filing

Windtree Therapeutics Reports Third Quarter 2023 Financial Results and Provides Key Business Updates

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.98

WINDTREE THERAPEUTICS INC /DE/ entered into At The Market Offering Agreement with Ladenburg Thalmann & Co. Inc. valued at up to $2,054,024 (effective 2023-11-09).

Action: entry
Agreement: atm program
Counterparty: Ladenburg Thalmann & Co. Inc.
Value: up to $2,054,024
Effective: 2023-11-09

Exact text from the filing

On November 9, 2023, Windtree Therapeutics, Inc. (the “ Company ”), entered into an At The Market Offering Agreement (the “ Sales Agreement ”) with Ladenburg Thalmann & Co. Inc. (“ Ladenburg ”), under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.001 per share (the “ Shares ”), initially having an aggregate offering price of up to $2,054,024 through Ladenburg as agent and/or principal (the “ Offering ”).

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.98

WINDTREE THERAPEUTICS INC /DE/ terminated Prior At The Market Offering Agreement with Ladenburg Thalmann & Co. Inc. valued at terminated (effective 2023-11-09).

Action: termination
Agreement: atm program
Counterparty: Ladenburg Thalmann & Co. Inc.
Value: terminated
Effective: 2023-11-09

Exact text from the filing

On November 9, 2023, the Company and Ladenburg, in connection with entering into the Sales Agreement, jointly terminated the At The Market Offering Agreement, dated as of September 17, 2020, by and between the Company and Ladenburg (the “ Prior Sales Agreement ”).

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

WINDTREE THERAPEUTICS INC /DE/ filing history →

Source: SEC EDGAR

accession 0001437749-23-031280

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.